Bernsen M R, Dullens H F, Den Otter W, Heintz P M
Department of Functional Morphology, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
J Interferon Cytokine Res. 1995 Jul;15(7):641-5. doi: 10.1089/jir.1995.15.641.
Other groups have reported a superior antitumor efficacy of polyethylene glycol-modified interleukin-2 (PEG-IL-2) compared with regular recombinant interleukin-2 (rIL-2). However, detailed comparison of the antitumor efficacies of locally applied PEG-IL-2 and rIL-2 in the well-established DBA/2-SL2 model shows a higher antitumor efficacy of PEG-IL-2 only at doses < 800 micrograms IL-2 protein/kg body weight. At doses > 800 micrograms IL-2 protein/kg body weight, rIL-2 has better therapeutic efficacy. The superiority of rIL-2 at doses > 800 micrograms IL-2 protein/kg body weight is a result of the toxicity of PEG-IL-2 at these doses. With either IL-2 preparation, cure rates of approximately 90% can be obtained at nontoxic doses. We conclude that PEG-IL-2 does not have superior antitumor efficacy to rIL-2. The main advantage of PEG-IL-2 is that for optimal therapeutic efficacy a daily injection schedule is not required as seems to be the case for rIL-2.
其他研究小组报告称，与常规重组白细胞介素-2（rIL-2）相比，聚乙二醇修饰的白细胞介素-2（PEG-IL-2）具有更强的抗肿瘤疗效。然而，在成熟的DBA/2-SL2模型中，对局部应用的PEG-IL-2和rIL-2的抗肿瘤疗效进行详细比较后发现，仅在白细胞介素-2蛋白剂量<800微克/千克体重时，PEG-IL-2才具有更高的抗肿瘤疗效。当白细胞介素-2蛋白剂量>800微克/千克体重时，rIL-2具有更好的治疗效果。在白细胞介素-2蛋白剂量>800微克/千克体重时，rIL-2的优势源于该剂量下PEG-IL-2的毒性。使用任何一种白细胞介素-2制剂，在无毒剂量下均可获得约90%的治愈率。我们得出结论，PEG-IL-2并不比rIL-2具有更强的抗肿瘤疗效。PEG-IL-2的主要优势在于，与rIL-2不同，它无需每日注射即可达到最佳治疗效果。
